Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD

Proc Am Thorac Soc. 2012 May;9(2):47-51. doi: 10.1513/pats.201201-009MS.

Abstract

A growing body of evidence indicates that oxidative stress plays a central role in the progression of chronic obstructive pulmonary disease (COPD). Chronic oxidative stress caused by cigarette smoke generates damage-associated molecular patterns (DAMPs), such as oxidatively or nitrosatively modified proteins and extracellular matrix fragments, which induce abnormal airway inflammation by activating innate and adaptive immune responses. Furthermore, oxidative stress-induced histone deacetylase 2 (HDAC2) inactivity is implicated in amplifying inflammatory responses and corticosteroid resistance in COPD. Oxidative stress also mediates disruption of innate immune defenses, which is associated with acute exacerbation of COPD. Host defense transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates a multifaceted cytoprotective response to counteract oxidative stress-induced pathological injuries. A decrease in Nrf2 signaling is associated with the progression of diseases. Recent evidence indicates that targeting Nrf2 can be a novel therapy to mitigate inflammation, improve innate antibacterial defenses, and restore corticosteroid responses in patients with COPD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems
  • Humans
  • Inflammation / complications
  • Inflammation / prevention & control*
  • NF-E2-Related Factor 2 / drug effects
  • NF-E2-Related Factor 2 / physiology*
  • Oxidative Stress*
  • Pulmonary Disease, Chronic Obstructive / complications*
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / prevention & control*
  • Signal Transduction

Substances

  • NF-E2-Related Factor 2
  • NFE2L2 protein, human